ARTICLE | Financial News
Sigilon debuts with $23.5M series A
June 23, 2017 7:39 PM UTC
On June 21, Sigilon Therapeutics Inc. (Cambridge, Mass.) emerged from Flagship Pioneering's VentureLabs incubator with $23.5 million in series A funding from the VC.
The newco will use its biocompatible Afibromer technology to develop encapsulated cell therapies for hematologic, enzyme deficiency, endocrine and metabolic disorders...
BCIQ Company Profiles